Subscribe to Newsletter

Daniel Martin

The Power List 2014

aniel Martin

Daniel Martin was extensively involved in the development of the ganciclovir implant (and later valganciclovir) for the treatment of CMV retinitis, leading the clinical trials that resulted in FDA approval of both drugs. He also helped lead the CATT trial, which compared bevacizumab with ranibizumab for the treatment of wet AMD.

Part of the Power List 2014

The 100 most influential people

Who are the 100 most influential people in ophthalmology?
That’s the question we posed to ourselves – and then to you – over two months ago, ahead of open nominations and a painstaking judging process. Here, without further ado, we celebrate the answer.

Go to The Power List 2014

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine



The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: